Amylin Pharmaceuticals Files Suit Against Eli Lilly

Amylin Pharmaceuticals, Inc. AMLN today announced that it has filed a lawsuit against Eli Lilly and Company LLY in the United States District Court for the Southern District of California, alleging that Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide. In 2002, Amylin entered an alliance with Lilly for the global development and commercialization of exenatide, a medicine indicated as a first line treatment for type 2 diabetes that is currently marketed as BYETTA injection. Exenatide is also the active ingredient in BYDUREON, a once-weekly version currently under review by the FDA.